Clinical Trials
14 trialsNCT03789097 2026-05-22
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT03515174 2025-04-10
Trial Comparing Active Intervention At Diagnosis With Usual Care to Improve Psycho-social Care in AYAO
National Cancer Centre, Singapore
Phase NA Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT01421524 2023-12-12
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
Phase 1 Completed
NCT01572493 2023-03-06
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01644968 2022-05-17
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
Providence Health & Services
Phase 1 Completed
NCT01353625 2021-10-05
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
Phase 1 Completed
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT01916135 2020-04-27
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02192346 2018-08-17
α-TEA in Advanced Cancer
Providence Health & Services
Phase 1 Completed
NCT01467635 2016-07-13
EBUS-TBNA Versus EBUS-TBNB
Royal Brompton & Harefield NHS Foundation Trust
Phase NA Withdrawn
NCT01026415 2014-12-18
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed
NCT01479023 2013-12-20
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT00466583 2011-07-07
Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma
Enzon Pharmaceuticals, Inc.
Phase 1 Completed